BKI-1369 manufacturers
- BKI-1369
-
- $474.00 / 5mg
-
2024-10-28
- CAS:1951431-22-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | BKI-1369 Basic information |
| Product Name: | BKI-1369 | | Synonyms: | BKI-1369;BKI1369,BKI 1369;1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-(2-ethoxy-6-quinolinyl)-1-[(1-methyl-4-piperidinyl)methyl]- | | CAS: | 1951431-22-3 | | MF: | C23H27N7O | | MW: | 417.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1951431-22-3.mol |  |
| | BKI-1369 Chemical Properties |
| Boiling point | 626.8±50.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 50 mg/mL (119.76 mM) | | pka | 9.02±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | BKI-1369 Usage And Synthesis |
| Description | BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves[1].
IC50: 1.52 μM (hERG)[1] | | References | [1]. Lee S, et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis. Antimicrob Agents Chemother. 2018 Jun 26;62(7). |
| | BKI-1369 Preparation Products And Raw materials |
|